After GST jitters, pharma market back on growth track in August

Zydus Cadila had the highest growth rate of 15.7%, followed by Mankind Pharma's 11.1%

After slipping into the negative in July, thanks to a temporary slowdown in drug sales caused by the transition to the Goods and Services Tax (GST), the Indian pharmaceutical market (IPM) was back on track in August, registering 2.4 per cent year-on-year (YoY) growth during the month. 

Data from market research firm AIOCD-AWACS show that the market witnessed a slight recovery in August, growing 2.4 per cent. Segment-wise, anti-infectives have declined by eight per cent during the month, while dermatology is still posting a double-digit positive growth of 12.7 per cent. The gastrointestinal segment has grown by 2.4 per cent,